Finance & Business World

The Translational Genomics Research Institute and Scottsdale Healthcare are testing an Italian pharmaceutical firm’s new drug for thymic cancer.

Scottsdale Healthcare is the world’s first site for the Phase I trial of a new oral drug, being called NMS-1286937. The hospital had conducted a Phase II trial for another of the Italian company’s drugs, called PHA-848125ac for advanced thymic cancer. This new research is based on the earlier promising results of PHA.

The thymus is a small organ near the lungs and heart that is a key part to the body’s immune system during fetal and childhood development.

The Italian company, called Nerviano Medical Sciences, is working in conjunction with TGen and SHC on both the thymic cancer drugs. The goal is to quickly turn these discoveries into targeted therapies at SHC’s Virginia G paydayloans. Piper Cancer Center in Scottsdale.

Mark Slater, senior vice president of research at Scottsdale Healthcare, said while SHC is the only U.S. site for the study, France and Italy also are conducting studies.

“Our partnership with TGen has allowed us to bring in novel therapies, really cutting-edge treatments that have addressed new mechanisms for rare cancers and cancers that have not responded well to standard therapy,” Slater said. “Our approach is to target our therapies using advanced molecular diagnostics.”

Source